Breaking barriers in rare disease drug development
Bringing rare disease treatments from pipeline to patient Rare diseases affect more than 395 million people worldwide, yet only 5% have an FDA-approved treatment. The challenges of small patient populations, regulatory complexities, and limited clinical data have historically slowed progress. But the landscape is changing. This infographic explores the key barriers in rare disease drug […]
The ‘Doing now what patients need next’ portfolio approach
Among all the corporate presentations at the 2025 J.P. Morgan Healthcare Conference, one small graphic from Roche (page 7), along with its purpose statement of “Doing now what patients need next”, stood out. The analysis was of how Roche’s product portfolio stacks up against global disease burden, both now and 10 years in the future. […]
Assessing current AI trends in drug development: Operational efficiency and overcoming challenges (part 2)
Artificial intelligence (AI) has shifted from experimental projects to a valuable pharmaceutical research and development (R&D) asset. While the pace of adoption varies across the industry, AI is enabling organizations to address inefficiencies, reduce timelines, and improve decision-making at critical drug development stages. Building on the insights from part 1, which highlighted how companies are […]
Unstructured EMR data expands cohort identification by 1,500%
By using integrated EMR, lab and claims data, Panalgo was able to provide the manufacturer with a rich longitudinal history for all identified patients.
Powering unbiased outcomes research with longitudinal data
The Panalgo team linked its unstructured EMR data, powered by NorstellaLinQ, to its closed claims data for a comprehensive, unbiased analysis. Within eight weeks, the client had access to years of longitudinal arthroplasty data, representing both inpatient and outpatient procedures, to fuel its study.